Angiogenesis, Exudation, and Degeneration 2017

February 11, 2017
Mandarin Oriental, Miami, FL

Program Directors: Philip J. Rosenfeld, MD, PhD and Harry W. Flynn, Jr., MD
Course Associate Director: Carmen A. Puliafito, MD, MBA

PROGRAM
Subject to Change

Saturday, February 11, 2017

7:00 am  Registration and Continental Breakfast

7:55  Welcome and Overview
Philip J. Rosenfeld, MD, PhD; Harry W. Flynn, Jr., MD; and Carmen A. Puliafito, MD, MBA

Session I: Age-Related Macular Degeneration
Moderators: Philip J. Rosenfeld, MD, PhD, Wen-Hsiang Lee, MD, PhD

8:00  Genetics and Nutrition in AMD
Emily Y. Chew, MD

8:10  The Oil Spill Strategies for AMD: Update and Model System
Christine A. Curcio, PhD, FARVO

8:20  Cuticular Drusen: New Clinical Pathological Observations
Lawrence A. Yannuzzi, MD

8:30  Update from CAM: A Proposed Classification System for Atrophy
SriniVas R. Sadda, MD

8:40  Using AMD Geographic Atrophy Area as a Clinical Trial Primary Outcome Variable
Frederick L. Ferris, III, MD

8:50  Genetic Variants and AMD Progression
Carel B. Hoyng, MD

9:00  Mechanisms of Low Luminance Vision Loss in AMD
Karl G. Csaky, MD, PhD
Computational Approaches to Modeling Compromise in the Choroidal Circulation
Philip Luthert, MB BS

Choriocapillaris Death is an Early Event in Neovascular AMD
Gerard A. Lutty, PhD

Session II: OCT Angiographic Imaging
Moderator: Carmen A. Puliafito, MD, MBA, Andrew A. Moshfeghi, MD, MBA

The Role of the Choriocapillaris in Non-Exudative AMD:
An OCT Angiography Based Evaluation
Nadia Waheed, MD

VISTA – Making OCTA Quantifiable
Jay S. Duker, MD

OCT Angiographic Prevalence and Natural History of Non-Exudative Neovascular AMD
Joao Rafael De Oliveira Dias, MD

SD-OCTA vs. SS-OCTA Imaging of CNV in AMD
Andrew R. Miller, BS

Biomarkers of Neovascular Activity Using OCT Angiography
David Sarraf, MD

Session III: Emerging Therapies
Moderators: Philip J. Rosenfeld, MD, PhD, Zohar Yehoshua, MD, MHA

Top Innovations in Retina – A VC’s Perspective
Emmett T. Cunningham, Jr., MD, PhD, MPH

Lipids as Therapeutic Targets in Dry AMD
Rajendra S. Apte, MD, PhD

Macrophage Polarization as Therapeutic Target in Dry AMD
Shelley Boyd, DABO, MD, FRCS(C), BSc

Update of Elamipretide (MTP-131) for Dry AMD
Scott W. Cousins, MD

Complement C3 Inhibition in AMD
Cedric G. Francois, MD, PhD

Development of a MAC Inhibitor for Dry AMD Using a Gene Therapy Approach
Elias Reichel, MD
11:20 Intravitreal Approaches to Retinal Gene Therapy: Results from Second Generation Vectors and Molecules
   David M. Brown, MD, FACS

11:30 Technical Aspects of Gene Delivery in AMD by Sub Retinal Surgical Approaches: Imaging Results and the Efficacy Impact of Location of Injection and Choice of Agent
   Szilárd Kiss, MD

11:40 A Sustained Release Liposomal Delivery System
   Peter K. Kaiser, MD

Session IV: Neovascular Age-Related Macular Degeneration
Moderators: Carmen A. Puliafito, MD, MBA, Lawrence J. Singerman, MD, FACS

11:50 Incidence of New Choroidal Neovascularization in Fellow Eyes of Patients Treated in the VIEW Trials
   K. Bailey Freund, MD

12:00 Long-Term Treatment with Intravitreal Aflibercept Injection in Patients Completing the VIEW and VIEW 1 Extension Studies: Two Year Results of the RANGE Study
   W. Lloyd Clark, MD

12:10 Long Term Outcomes in Patients Treated for Neovascular AMD
   Daniel F. Martin, MD

12:20 Five-year morphology-visual acuity correlations in CATT
   Glenn J. Jaffe, MD

12:30 Progression Rate of RPE Loss in Patients with Neovascular AMD Treated with Different VEGF Inhibitors
   Stephan Michels, MD MBA

12:40 Risk Factors for Fibrosis in the Anti-VEGF Era
   Usha Chakravarthy, MD

12:50 Functional and Anatomic Outcomes 1 Year Following Conversion to Conbercept in Chinese Patients with Neovascular Age-Related Macular Degeneration:
   Xiaodong Sun, MD

1:00 Brolucizumab vs. Aflibercept Treatment for Neovascular AMD
   Lawrence J. Singerman, MD, FACS

1:10 Lunch
Session V: Neovascular AMD: Combination Therapies
Moderator: Carmen A. Puliafito, MD, MBA, Philip J. Rosenfeld, MD, PhD

2:10  Combination Therapy with Aflibercept for the Treatment of Neovascular AMD
      Jeffrey S. Heier, MD

2:20  RG7716: A Novel Anti-VEGF/Anti-Angiopoietin2 Bispecific Monoclonal
      Antibody for AMD and DME
      Pravin U. Dugel, MD

2:30  Icon-1 in the Treatment of Neovascular AMD: Phase 2a Study Results
      Carl D. Regillo, MD, FACS

2:40  Topical Squalamine for Neovascular AMD: An Update
      Jason S. Slakter, MD

Session VI: Stem Cells and Retinal Degenerations
Moderator: Thomas A. Albini, MD, Ninel Z. Gregori, MD

2:50  Patient-Funded Stem Cell Therapies: A Report of Three Cases and Their Clinical and
      Regulatory Context
      Thomas A. Albini, MD

3:00  Long-Term Outcomes of hESC-Derived RPE Cell Transplantation in Atrophic AMD and
      Stargardt Disease
      Ninel Z. Gregori, MD

3:10  Stem Cell Derived RPE Transplantation - An Update of the London Project
      Lyndon Da Cruz, MD

3:20  Subretinal Transplantation of RPE Cells Derived from Human Embryonic Stem Cells in
      Patients with Advanced Dry AMD: Observations from the Hadassah Phase I/IIa Clinical
      Trial
      Eyal Banin, MD PhD

3:30  Autologous iPSC-RPE Cell Therapy for AMD
      Kapil Bharti, PhD

3:40  Clinical Translation of Retinal Progenitors Cells for RP: The jCyte Experience
      Henry J. Klassen, MD PhD

3:50  Update on Clinical Trials for Retinal Degenerations
      Byron L. Lam, MD
Session VII: Diabetic Retinopathy  
Moderator: Harry W. Flynn, Jr., MD, Justin Townsend, MD

4:00  DRCR.net Update  
Harry W. Flynn, Jr., MD

4:10  Slurry Kenalog: A Lower Cost, Quick and Easy Alternative for Long-Term Intraocular Steroid Delivery  
Susan M. Malinowski, MD, FACS

4:20  Anti-Integrin Treatment for Diabetic Edema  
David S. Boyer, MD

4:30  Phase 1 Open-Label, Single-Center Study to Evaluate the Safety and Tolerability of Topical Ocular PAN-90806 in Patients with Proliferative Diabetic Retinopathy (PDR)  
Victor H. Gonzalez, MD

4:40  Update on Aflibercept Pharmacokinetics and Treatment of Diabetic Macular Edema  
Diana V. Do, MD

4:50  Ziv-Aflibercept in Diabetic Macular Edema  
Michel E. Farah, MD

5:00  ENDURANCE Extension Study Following the VISTA DME Study  
Charles C. Wykoff, MD PhD

5:10  Peripheral and Macular Retinal Vascular Perfusion and Leakage Dynamics in Diabetic Macular Edema and Retinal Venous Occlusions During Intravitreal Aflibercept Injection Treatment for Retinal Edema: PERMEATE Study  
Justis P. Ehlers, MD

5:20  Impact of Cataract Surgery on Visual Acuity and OCT in DME Patients Undergoing Anti-VEGF Therapy  
Andrew A. Moshfeghi, MD, MBA

Session VIII: Uveitis and Retinal Vascular Diseases  
Moderator: Jaclyn L. Kovach, MD, Philip J. Rosenfeld, MD, PhD

5:30  Intravitreal Sirolimus for Non-Infectious Uveitis: Primary Outcomes of the Phase3 SAKURA 2 Study  
Quan D. Nguyen, MD, MSc

5:40  Suprachoroidal Triamcinolone Acetonide for Retinal Vein Occlusion: Results of the Tanzanite Trial  
Peter A. Campochiaro, MD
5:50  MacTel Project Update
     Martin Friedlander, MD, PhD

6:00  Near-Term Safety of Bevacizumab in Treatment of Retinopathy of Prematurity
     Darius M. Moshfeghi, MD

6:10  Advances in Mobile Device Enabled Retinal Fundus Photography for Clinical Research
     and Public Health Screening
     Mark S. Blumenkranz, MD

6:20  Adjourn/Cocktail Reception